Advertisement

Science China Life Sciences

, Volume 59, Issue 11, pp 1139–1148 | Cite as

Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study

  • Xiangyu Zhao
  • Feng Gao
  • Xiaohui Zhang
  • Yu Wang
  • Lanping Xu
  • Kaiyan Liu
  • Xiaosu Zhao
  • Yingjun Chang
  • Han Wei
  • Huan Chen
  • Yuhong Chen
  • Zhengfan Jiang
  • Xiaojun HuangEmail author
Open Access
Research Paper

Abstract

The effects of haploidentical rhG-CSF-mobilized blood and marrow transplantation (HBMT) on hematological malignances are well established. Previous prospective single-center studies have demonstrated better survival after HBMT versus haploidentical rhG-CSF-mobilized peripheral blood stem cell transplantation (HPBSCT) for acute leukemia (AL) not in remission (NR) or in more than the second complete remission (>CR2). To test the hypothesis that HBMT is still superior to HPBSCT for patients with AL, multiple myeloma (MM), or non-Hodgkin lymphoma (NHL) in CR1/CR2 and for patients with chronic myeloid leukemia in the first and second chronic phase lacking a matched donor, we designed a propensity score method-based multicenter study. Hematopoietic recovery, acute graft-versus-host disease (aGVHD), and chronic GVHD were comparable between the HBMT group (n=168) and the HPBSCT group (n=42). No significant differences were found in non-relapse mortality rate (20.17%±3.58% and 27.24%±7.16%, P=0.18) or relapse rate (19.96%±3.72% and 28.49%±8.25%, P=0.32) between the HBMT group and the HPBSCT group. HBMT recipients had better overall survival (65.0%±4.2% and 54.2%±8.3%, P=0.037) and disease-free survival (59.9%±4.6% and 44.3%±8.7%, P=0.051). Multivariate analysis showed that HPBSCT was associated with poorer DFS (HR (95%CI), 1.639 (0.995–2.699), P=0.052). Our comparisons showed that HBMT was superior to HPBSCT as a post-remission treatment for patients lacking an identical donor.

Keywords

HBMT GPB Beijing Protocol HSCT 

References

  1. Apperley, J., Niederwieser, D., Huang, X., Nagler, A., Fuchs, E., Szer, J., and Kodera, Y. (2016). Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant 22, 23–26.CrossRefPubMedGoogle Scholar
  2. Aversa, F. (2005). Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23, 3447–3454.CrossRefPubMedGoogle Scholar
  3. Bashey, A., Zhang, X., Sizemore, C.A., Manion, K., Brown, S., Holland, H.K., Morris, L.E., and Solomon, S.R. (2013). T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 31, 1310–1316.CrossRefPubMedGoogle Scholar
  4. Bradstock, K., Bilmon, I., Kwan, J., Blyth, E., Micklethwaite, K., Huang, G., Deren, S., Byth, K., and Gottlieb, D. (2015). Influence of stem cell source on outcomes of allogeneic reduced-intensity conditioning therapy transplants using haploidentical related donors. Biol Blood Marrow Transplant 21, 1641–1645.CrossRefPubMedGoogle Scholar
  5. Castagna, L., Crocchiolo, R., Furst, S., Bramanti, S., El Cheikh, J., Sarina, B., Granata, A., Mauro, E., Faucher, C., Mohty, B., Harbi, S., Chabannon, C., Carlo-Stella, C., Santoro, A., and Blaise, D. (2014). Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 20, 724–729.CrossRefPubMedGoogle Scholar
  6. Chang, Y.J., and Huang, X.J. (2011). Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review. Clin Transplant 25, 13–23.CrossRefPubMedGoogle Scholar
  7. Chang, Y.J., Zhao, X.Y., and Huang, X.J. (2014). Immune reconstitution after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20, 440–449.CrossRefPubMedGoogle Scholar
  8. Di Bartolomeo, P., Santarone, S., De Angelis, G., Picardi, A., Cudillo, L., Cerretti, R., Adorno, G., Angelini, S., Andreani, M., De Felice, L., Rapanotti, M.C., Sarmati, L., Bavaro, P., Papalinetti, G., Di Nicola, M., Papola, F., Montanari, M., Nagler, A., and Arcese, W. (2013). Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 121, 849–857.CrossRefPubMedGoogle Scholar
  9. Filipovich, A.H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J.R., Lee, S.J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., Cowen, E.W., Dinndorf, P., Farrell, A., Hartzman, R., Henslee-Downey, J., Jacobsohn, D., McDonald, G., Mittleman, B., Rizzo, J.D., Robinson, M., Schubert, M., Schultz, K., Shulman, H., Turner, M., Vogelsang, G., and Flowers, M.E.D. (2005). National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 11, 945–956.CrossRefPubMedGoogle Scholar
  10. Huang, X.J., Liu, D.H., Liu, K.Y., Xu, L.P., Chen, H., and Han, W. (2007). Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 92, 414–417.CrossRefPubMedGoogle Scholar
  11. Huang, X.J., Liu, D.H., Liu, K.Y., Xu, L.P., Chen, H., Han, W., Chen, Y.H., Wang, J.Z., Gao, Z.Y., Zhang, Y.C., Jiang, Q., Shi, H.X., and Lu, D.P. (2006). Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 38, 291–297.CrossRefPubMedGoogle Scholar
  12. Huang, X.J., Liu, D.H., Liu, K.Y., Xu, L.P., Chen, Y.H., Wang, Y., Han, W., and Chen, H. (2008a). Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 28, 276–283.CrossRefPubMedGoogle Scholar
  13. Huang, X.J., Wang, Y., Liu, D.H., Xu, L.P., Chen, H., Chen, Y.H., Han, W., Shi, H.X., and Liu, K.Y. (2008b). Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia—feasibility and safety study. J Clin Immunol 28, 390–397.CrossRefPubMedGoogle Scholar
  14. Huang, X.J., Wang, Y., Liu, D.H., Xu, L.P., Liu, K.Y., Chen, H., Chen, Y.H., Han, W., and Shi, H.X. (2009). Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant 44, 309–316.CrossRefPubMedGoogle Scholar
  15. Lv, M., and Huang, X.J. (2015). Fighting against hematological malignancy in China: from unique system to global impact. Sci China Life Sci 58, 1183–1190.CrossRefPubMedGoogle Scholar
  16. Mo, X.D., Xu, L.P., Liu, D.H., Chen, Y.H., Han, W., Zhang, X.H., Chen, H., Wang, Y., Wang, J.Z., Liu, K.Y., and Huang, X.J. (2012). Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT. Bone Marrow Transplant 47, 1201–1205.CrossRefPubMedGoogle Scholar
  17. Mo, X.D., Xu, L.P., Liu, D.H., Zhang, X.H., Chen, H., Chen, Y.H., Han, W., Wang, Y., Wang, F.R., Wang, J.Z., Liu, K.Y., and Huang, X.J. (2013). Nonmalignant late effects in survivors of partially matched donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19, 777–783.CrossRefPubMedGoogle Scholar
  18. Mo, X.D., Zhao, X.Y., Liu, D.H., Chen, Y.H., Xu, L.P., Zhang, X.H., Chen, H., Han, W., Wang, Y., Wang, F.R., Wang, J.Z., Liu, K.Y., and Huang, X.J. (2014). Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances. Bone Marrow Transplant 49, 1070–1075.CrossRefPubMedGoogle Scholar
  19. Pessach, I., Resnick, I., Shimoni, A., and Nagler, A. (2015). G-CSF-primed BM for allogeneic SCT: revisited. Bone Marrow Transplant 50, 892–898.CrossRefPubMedGoogle Scholar
  20. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J., and Thomas, E.D. (1995). 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15, 825–828.PubMedGoogle Scholar
  21. Raiola, A.M., Dominietto, A., Ghiso, A., Di Grazia, C., Lamparelli, T., Gualandi, F., Bregante, S., Van Lint, M.T., Geroldi, S., Luchetti, S., Ballerini, F., Miglino, M., Varaldo, R., and Bacigalupo, A. (2013). Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 19, 117–122.CrossRefPubMedGoogle Scholar
  22. Solomon, S.R., Sizemore, C.A., Sanacore, M., Zhang, X., Brown, S., Holland, H.K., Morris, L.E., and Bashey, A. (2012). Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 18, 1859–1866.CrossRefPubMedGoogle Scholar
  23. Wang, Y., Chang, Y.J., Xu, L.P., Liu, K.Y., Liu, D.H., Zhang, X.H., Chen, H., Han, W., Chen, Y.H., Wang, F.R., Wang, J.Z., Chen, Y., Yan, C.H., Huo, M.R., Li, D., and Huang, X.J. (2014a). Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood 124, 843–850.CrossRefPubMedGoogle Scholar
  24. Wang, Y., Fu, H.X., Liu, D.H., Xu, L.P., Zhang, X.H., Chang, Y.J., Chen, Y.H., Wang, F.R., Sun, Y.Q., Tang, F.F., Liu, K.Y., and Huang, X.J. (2014b). Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant 49, 426–433.CrossRefPubMedGoogle Scholar
  25. Wang, Y., Liu, D.H., Liu, K.Y., Xu, L.P., Zhang, X.H., Han, W., Chen, H., Chen, Y.H., Wang, F.R., Wang, J.Z., Sun, Y.Q., and Huang, X.J. (2013). Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer 119, 978–985.CrossRefPubMedGoogle Scholar
  26. Wang, Y., Liu, D.H., Xu, L.P., Liu, K.Y., Chen, H., Zhang, X.H., Chen, Y.H., Han, W., Wang, F.R., Wang, J.Z., Yan, C.H., and Huang, X.J. (2012). Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 47, 1099–1104.CrossRefPubMedGoogle Scholar
  27. Xiao-Jun, H., Lan-Ping, X., Kai-Yan, L., Dai-Hong, L., Yu, W., Huan, C., Yu-Hong, C., Wei, H., Jing-Zhi, W., Yao, C., Xiao-Hui, Z., Hong-Xia, S., Feng-Rong, W., and Fei-Fei, T. (2009). Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 15, 4777–4783.CrossRefPubMedGoogle Scholar
  28. Xu, L.P., Liu, K.Y., Liu, D.H., Chen, H., Han, W., Chen, Y.H., Wang, Y., and Huang, X.J. (2010). The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. Bone Marrow Transplant 45, 985–992.CrossRefPubMedGoogle Scholar
  29. Zhao, X., Chen, Y., Zhao, X., Liu, D., Xu, L., Wang, Y., Han, W., Chen, Y., Chen, H., Zhang, X., Liu, K., and Huang, X. (2013). Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia. Clin Transplant 27, 844–851.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2016

Authors and Affiliations

  • Xiangyu Zhao
    • 1
  • Feng Gao
    • 2
  • Xiaohui Zhang
    • 1
  • Yu Wang
    • 1
    • 3
  • Lanping Xu
    • 1
  • Kaiyan Liu
    • 1
  • Xiaosu Zhao
    • 1
    • 3
  • Yingjun Chang
    • 1
    • 3
  • Han Wei
    • 1
  • Huan Chen
    • 1
  • Yuhong Chen
    • 1
  • Zhengfan Jiang
    • 4
    • 5
  • Xiaojun Huang
    • 1
    • 3
    • 5
    Email author
  1. 1.Peking University People’s Hospital & Institute of HematologyBeijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijingChina
  2. 2.North China University of Science and Technology Affiliated HospitalTangshanChina
  3. 3.Peking University Qinghe HospitalBeijingChina
  4. 4.State Key Laboratory of Protein and Plant Gene Research, Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life SciencesPeking UniversityBeijingChina
  5. 5.Peking-Tsinghua Center for Life SciencesBeijingChina

Personalised recommendations